ReviewOncoTargets and therapy2023

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.

Leticia Varella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.